Bausch & Lomb Corp (BLCO) Stock Price, Quote & News

Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeut...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 905 695 7700

Website: www.bausch.com

Address:

520 Applewood Crescent, Vaughan, Canada

89quattro Sep. 11 at 11:58 AM

$BHC $BLCO St. Jude the Apostle is the patron saint of lost causes and impossible situations. At this point I doubt that even he could help this mess.

0 · Reply

Sciguy67 Sep. 2 at 8:26 PM

$BLCO BO announcement by EOY 22-24 a share

0 · Reply

Coolhat1 Sep. 2 at 8:04 PM

$BHC $BLCO above 18😏

0 · Reply

TickrTalk0007 Aug. 31 at 3:16 PM

$BLCO when you have nothing innovative in your pipeline, you throw good money at bad data and try to revive the pipeline.... wasting money on failed Ph 2

0 · Reply

prismmarketview Aug. 26 at 2:41 PM

Bausch + Lomb is taking its dual-action dry eye drop to Phase 3 after a Phase 2 study told it when to measure. The combination showed a significant improvement over Xiidra alone at Day 15, ahead of the Day 29 timepoint the company had originally chosen. The FDA accepts Day 15 for registrational studies, so the pivotal program will be built around it. In dry eye, knowing when to measure can matter as much as what you are measuring. Aldeyra, Palatin and OKYO are each working through their own version of that question. $BLCO $ALDX $PTN $OKYO https://prismmarketview.com/bausch-lomb-missed-its-dry-eye-endpoint-the-result-still-points-to-phase-3/

0 · Reply

Stock_Spectator Aug. 25 at 2:56 PM

$BLCO $BHC Thomas J. Appio is the Chairman of the Board of Bausch + Lomb Corporation (NYSE: BLCO).He assumed the role on August 10, 2026, succeeding Brent Saunders, who continues to serve as a member of the board while remaining the company's Chief Executive Officer. Appio is also the CEO of Bausch Health Companies Inc.

0 · Reply

kbingo12 Aug. 21 at 3:33 PM

$BLCO Appio new Chairman of Board is not a good thing. Brent leaving soon is my guess.

3 · Reply

Contrarian_Dan Aug. 20 at 1:19 PM

$BLCO is a purchase offer for the company offer incoming?

1 · Reply

Coolhat1 Aug. 19 at 1:47 PM

$BHC $BLCO both moving higher and the new board at blco seems really promising

0 · Reply

Coolhat1 Aug. 18 at 2:24 PM

$BLCO $BHC wow what’s happens both rising

2 · Reply

Bausch + Lomb announces European CE Mark approval of SeeLyra

BLCO

Sep 11, 2026, 6:11 AM EDT - 2 days ago

Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser

2026-09-09T12:15:20.000Z - 4 days ago

Leerink bullish on Bausch + Lomb, initiates with an Outperform

BLCO

2026-09-09T10:15:19.000Z - 4 days ago

Bausch + Lomb initiated with an Outperform at Leerink

BLCO

2026-09-02T11:10:21.000Z - 11 days ago

Bausch + Lomb publishes new research on en Vista Aspire IOLs

BLCO

Sep 2, 2026, 7:00 AM EDT - 11 days ago

Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience

Sep 1, 2026, 6:58 AM EDT - 12 days ago

Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds

Aug 24, 2026, 5:30 PM EDT - 19 days ago

Bausch + Lomb Transcript: Study result

Aug 24, 2026, 5:30 PM EDT - 19 days ago

Bausch + Lomb Slides: Study result

Aug 24, 2026, 5:30 PM EDT - 19 days ago

Bausch + Lomb Press release: Study result

2026-08-06T11:33:35.000Z - 5 weeks ago

Bausch + Lomb announces Board of Directors update

BLCO

2026-08-06T11:25:39.000Z - 5 weeks ago

Bausch + Lomb reaffirms FY26 revenue $5.44B-$5.54B, consensus $5.49B

BLCO

Aug 6, 2026, 7:04 AM EDT - 5 weeks ago

Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board

BHC

Aug 6, 2026, 7:00 AM EDT - 5 weeks ago

Bausch + Lomb Announces Board of Directors Update, Reaffirms Guidance

2026-08-03T10:10:32.000Z - 5 weeks ago

Bausch + Lomb price target raised to $21 from $20 at H.C. Wainwright

BLCO

2026-07-30T13:23:20.000Z - 6 weeks ago

Bausch + Lomb price target raised to $23 from $21 at UBS

BLCO

Jul 29, 2026, 8:00 AM EDT - 6 weeks ago

Bausch + Lomb Earnings Call Transcript: Q2 2026

Jul 29, 2026, 8:00 AM EDT - 6 weeks ago

Bausch + Lomb Earnings release: Q2 2026

Jul 29, 2026, 8:00 AM EDT - 6 weeks ago

Bausch + Lomb Slides: Q2 2026

Jul 29, 2026, 8:00 AM EDT - 6 weeks ago

Bausch + Lomb Quarterly report: Q2 2026

Jul 29, 2026, 7:57 AM EDT - 6 weeks ago

Bausch + Lomb Upgrades Full-Year Outlook on Strong Quarter

2026-07-29T11:06:34.000Z - 6 weeks ago

Bausch + Lomb reports Q2 adjusted EPS 15c, consensus 16c

BLCO

2026-07-29T11:05:49.000Z - 6 weeks ago

Bausch + Lomb raises FY26 revenue view to $5.440B-$5.540B from $5.420B-$5.520B

BLCO

Jul 29, 2026, 6:58 AM EDT - 6 weeks ago

Bausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 Guidance

2026-07-28T12:06:29.000Z - 6 weeks ago

Bausch + Lomb initiated with a Buy at UBS

BLCO

2026-07-28T10:46:22.000Z - 6 weeks ago

Bausch + Lomb initiated with a Buy at UBS

BLCO

2026-07-16T11:05:10.000Z - 1 month ago

Bausch + Lomb launches EyeGility Inserter in U.S.

BLCO

Jul 16, 2026, 7:00 AM EDT - 1 month ago

Bausch + Lomb Launches EyeGility™ Inserter Preloaded IOL Delivery System in the United States

2026-07-09T20:35:22.000Z - 2 months ago

Bausch + Lomb says Phase 2 study of BL1107 did not achieve primary endpoint

BLCO

Jul 9, 2026, 4:30 PM EDT - 2 months ago

Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate

2026-07-09T11:05:11.000Z - 2 months ago

Bausch + Lomb introduces Orphia AI-powered digital health platform

BLCO

Jul 9, 2026, 7:00 AM EDT - 2 months ago

Bausch + Lomb Introduces Orphia™, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care

2026-07-08T10:15:21.000Z - 2 months ago

Bausch + Lomb price target raised to $21 from $19 at Citi

BLCO

2026-07-06T12:46:45.000Z - 2 months ago

Bausch + Lomb price target raised to $17 from $16 at Evercore ISI

BLCO

Jul 6, 2026, 7:15 AM EDT - 2 months ago

Bausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29

2026-07-01T11:11:48.000Z - 2 months ago

Bausch + Lomb announces new findings from third State of Dry Eye survey

BLCO

Jul 1, 2026, 7:00 AM EDT - 2 months ago

New Bausch + Lomb Data Show that Addressing Dry Eye Symptoms is Associated with Improved Quality of Life, Including Lower Anxiety and Increased Self-Confidence

Jun 9, 2026, 1:20 PM EDT - 3 months ago

Bausch + Lomb Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 1, 2026, 1:00 PM EDT - 3 months ago

Bausch + Lomb Transcript: R&D Day 2026

Jun 1, 2026, 1:00 PM EDT - 3 months ago

Bausch + Lomb Slides: FY 2026

Jun 1, 2026, 6:59 AM EDT - 3 months ago

Bausch + Lomb Launches Blink® Triple Care Preservative Free Lubricant Eye Drops in the United States

May 21, 2026, 7:15 AM EDT - 3 months ago

Bausch + Lomb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

May 20, 2026, 4:49 PM EDT - 3 months ago

Bausch + Lomb Announces 2026 Annual Meeting of Shareholder Results

May 20, 2026, 10:30 AM EDT - 3 months ago

Bausch + Lomb Transcript: AGM 2026

2026-05-19T11:10:10.000Z - 3 months ago

Bausch + Lomb announces U.S. launch of PreserVision AREDS3

BLCO

2026-05-07T14:16:04.000Z - 4 months ago

Bausch + Lomb launches Bi-Blade+ dual-port vitrectomy cutter in Europe

BLCO

May 6, 2026, 7:15 AM EDT - 4 months ago

Bausch + Lomb Announces Second R&D “Teach-in” Webinar

Apr 30, 2026, 7:00 AM EDT - 4 months ago

Bausch + Lomb to Feature More Than 40 Scientific Studies at the 2026 Association for Research in Vision and Ophthalmology Annual Meeting

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Bausch + Lomb Earnings Call Transcript: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Bausch + Lomb Earnings release: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Bausch + Lomb Slides: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Bausch + Lomb Quarterly report: Q1 2026

Apr 29, 2026, 6:58 AM EDT - 4 months ago

Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook

Apr 22, 2026, 7:15 AM EDT - 4 months ago

Bausch + Lomb Releases 2025 Sustainability Impact Report

Apr 16, 2026, 7:00 AM EDT - 5 months ago

Bausch + Lomb Reports Nearly 725,000 Pounds of Contact Lens, Lens Care and Eye Care Materials Collected and Recycled Through ONE By ONE Recycling Program

Apr 10, 2026, 8:00 AM EDT - 5 months ago

Bausch + Lomb Proxy statement: Proxy filing

$Bausch + Lomb Announces New Scientific Data, Educational Events at the American Society of Cataract and Refractive Surgery Annual Meeting$

Apr 6, 2026, 7:00 AM EDT - 5 months ago

Bausch + Lomb Announces New Scientific Data, Educational Events at the American Society of Cataract and Refractive Surgery Annual Meeting

Mar 30, 2026, 7:15 AM EDT - 5 months ago

Bausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29

Mar 23, 2026, 1:30 PM EDT - 5 months ago

Bausch + Lomb Transcript: Status update

Mar 23, 2026, 1:30 PM EDT - 5 months ago

Bausch + Lomb Press release: Status update

Mar 23, 2026, 1:30 PM EDT - 5 months ago

Bausch + Lomb Slides: Status update

Mar 23, 2026, 7:00 AM EDT - 5 months ago

Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma

Mar 13, 2026, 9:00 AM EDT - 6 months ago

Bausch + Lomb Corporation Investigated by the Portnoy Law Firm

Mar 9, 2026, 7:15 AM EDT - 6 months ago

Bausch + Lomb Launches R&D “Teach-in” Webinar Series

Feb 24, 2026, 7:00 AM EST - 6 months ago

Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®

Feb 18, 2026, 8:00 AM EST - 6 months ago

Bausch + Lomb Earnings Call Transcript: Q4 2025

Feb 18, 2026, 8:00 AM EST - 6 months ago

Bausch + Lomb Annual report: Q4 2025

Feb 18, 2026, 8:00 AM EST - 6 months ago

Bausch + Lomb Earnings release: Q4 2025

Feb 18, 2026, 8:00 AM EST - 6 months ago

Bausch + Lomb Slides: Q4 2025

Feb 18, 2026, 6:58 AM EST - 6 months ago

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance

Jan 20, 2026, 7:15 AM EST - 7 months ago

Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18

Jan 12, 2026, 4:30 PM EST - 8 months ago

Bausch + Lomb Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 4:30 PM EST - 8 months ago

Bausch + Lomb Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 7:00 AM EST - 8 months ago

Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.

Jan 2, 2026, 4:30 PM EST - 8 months ago

Bausch + Lomb Completes Refinancing of Outstanding Term B Loans

Dec 23, 2025, 7:30 AM EST - 8 months ago

Bausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 17, 2025, 4:30 PM EST - 8 months ago

Bausch + Lomb Announces Two Board of Directors Appointments

Dec 12, 2025, 4:48 PM EST - 9 months ago

Bausch + Lomb Announces Refinancing of Outstanding Term B Loans

Dec 3, 2025, 9:00 AM EST - 9 months ago

Bausch + Lomb Transcript: Citi Annual Global Healthcare Conference 2025

Nov 18, 2025, 4:30 PM EST - 9 months ago

Bausch + Lomb to Participate in Citi Global Healthcare Conference

Nov 13, 2025, 8:30 AM EST - 10 months ago

Bausch + Lomb Transcript: Investor Day 2025

Nov 13, 2025, 8:30 AM EST - 10 months ago

Bausch + Lomb Slides: FY 2025

Nov 10, 2025, 6:59 AM EST - 10 months ago

Bausch + Lomb Reports More Than 690,000 Pounds of Contacts Lens, Lens Care and Eye Care Materials Collected Through ONE By ONE Recycling Program

Oct 29, 2025, 8:00 AM EDT - 10 months ago

Bausch + Lomb Earnings Call Transcript: Q3 2025

Oct 29, 2025, 8:00 AM EDT - 10 months ago

Bausch + Lomb Quarterly report: Q3 2025

Oct 29, 2025, 8:00 AM EDT - 10 months ago

Bausch + Lomb Earnings release: Q3 2025

Oct 29, 2025, 8:00 AM EDT - 10 months ago

Bausch + Lomb Slides: Q3 2025

Oct 29, 2025, 6:58 AM EDT - 10 months ago

Bausch + Lomb Announces Third-Quarter 2025 Results

Oct 19, 2025, 8:00 PM EDT - 10 months ago

Activist Jana Takes Stake in Cooper, a Maker of Medical Devices

COO

Sep 29, 2025, 7:15 AM EDT - 11 months ago

Bausch + Lomb Will Release Third-Quarter 2025 Financial Results on Oct. 29 and Hold Investor Day on Nov. 13

Sep 8, 2025, 7:45 AM EDT - 1 year ago

Bausch + Lomb Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 7:00 AM EDT - 1 year ago

Bausch + Lomb Launches ASANA™ Gas Permeable Lenses in the United States

Aug 18, 2025, 5:01 PM EDT - 1 year ago

Bausch + Lomb Announces Board Changes

Aug 14, 2025, 7:15 AM EDT - 1 year ago

Bausch + Lomb to Participate in Upcoming Investor Conferences

Jul 30, 2025, 8:00 AM EDT - 1 year ago

Bausch + Lomb Earnings Call Transcript: Q2 2025

Jul 30, 2025, 8:00 AM EDT - 1 year ago

Bausch + Lomb Quarterly report: Q2 2025

Jul 30, 2025, 8:00 AM EDT - 1 year ago

Bausch + Lomb Earnings release: Q2 2025

Jul 30, 2025, 8:00 AM EDT - 1 year ago

Bausch + Lomb Slides: Q2 2025

Jul 30, 2025, 6:57 AM EDT - 1 year ago

Bausch + Lomb Announces Second-Quarter 2025 Results

Jul 1, 2025, 7:00 AM EDT - 1 year ago

Bausch + Lomb Combines Patient Voices and New Survey Insights to Combat Persistent Misconceptions about Dry Eye

Jun 30, 2025, 6:58 AM EDT - 1 year ago

Bausch + Lomb Will Release Second-Quarter 2025 Financial Results on July 30 and Hold Investor Day on Nov. 13

Jun 18, 2025, 4:30 PM EDT - 1 year ago

Bausch + Lomb Announces Pricing of Upsized Senior Secured Notes Offering

89quattro Sep. 11 at 11:58 AM

$BHC $BLCO St. Jude the Apostle is the patron saint of lost causes and impossible situations. At this point I doubt that even he could help this mess.

0 · Reply

Sciguy67 Sep. 2 at 8:26 PM

$BLCO BO announcement by EOY 22-24 a share

0 · Reply

Coolhat1 Sep. 2 at 8:04 PM

$BHC $BLCO above 18😏

0 · Reply

TickrTalk0007 Aug. 31 at 3:16 PM

$BLCO when you have nothing innovative in your pipeline, you throw good money at bad data and try to revive the pipeline.... wasting money on failed Ph 2

0 · Reply

prismmarketview Aug. 26 at 2:41 PM

0 · Reply

Stock_Spectator Aug. 25 at 2:56 PM

0 · Reply

kbingo12 Aug. 21 at 3:33 PM

$BLCO Appio new Chairman of Board is not a good thing. Brent leaving soon is my guess.

3 · Reply

Contrarian_Dan Aug. 20 at 1:19 PM

$BLCO is a purchase offer for the company offer incoming?

1 · Reply

Coolhat1 Aug. 19 at 1:47 PM

$BHC $BLCO both moving higher and the new board at blco seems really promising

0 · Reply

Coolhat1 Aug. 18 at 2:24 PM

$BLCO $BHC wow what’s happens both rising

2 · Reply

gary918 Aug. 12 at 2:34 PM

$BHC To the new Board Members at $BLCO. One week on the job and your options/grants are already 5% under water. Welcome to our world!

0 · Reply

OMillionaires Aug. 2 at 3:45 PM

$BHC closed up 14% on Friday after also rallying 28.9% on Thursday post earnings. The very interesting part of this was Friday saw more volume than Thursday and both sessions the stock closed near the HOD. $BHC is a debt story... nearly $20BIL - but they have been deleveraging and also generate over $1BIL in FC, not to mention have that $6BIL $BLCO stake. One of these days this stock starts to re-rate. This could be the start of it... or it could be next week, next month, or next year. But once is starts, will be $20+(and likely much higher) one to watch this coming week for confirmation...

0 · Reply

TickrTalk0007 Jul. 29 at 1:36 PM

$BLCO stock down 5%…. That’s how them apples are… company needs money- offering or debt (on top of already existing debt)🥶 Brent is going to quit

0 · Reply

EarningsInsider Jul. 29 at 1:31 PM

https://www.marketbeat.com/earnings/reports/2026-7-29-bausch-lomb-co-stock/ $BLCO Bausch + Lomb Earnings Transcript

0 · Reply

Rpate Jul. 29 at 1:18 PM

$BLCO Q2 2026 margin is 17.6% Q2 2025 margin was 15% FCF is positive. Great result in-line as expected.

0 · Reply

StocktwitsEarnings Jul. 29 at 1:08 PM

$BLCO Q2 '26 Earnings Results & Recap Bausch + Lomb raised its full-year 2026 revenue guidance to a range of $5.440B $5.540B and adjusted EBITDA excluding acquired IPR&D to a range of $1.025B $1.075B.

0 · Reply

Coolhat1 Jul. 29 at 11:21 AM

$BLCO @TickrTalk0007 how about them apples

1 · Reply

TraderJoe65 Jul. 23 at 1:19 PM

$LENZ is $BLCO going to buy LENZ or what

0 · Reply

TickrTalk0007 Jul. 11 at 12:34 PM

$BLCO worthless pipeline…Manisha did nothing right. Brent is going to be stuck for a while. Won’t be surprised if he takes paternity leave 🤣

0 · Reply

DoubleUpwithChuck Jul. 10 at 1:31 AM

$BLCO did they get a new ticker? Apparently i own this somewhere

0 · Reply

StocktwitsNews Jul. 9 at 11:10 PM

BLCO Stock Drops After-Hours — Bausch + Lomb Halts Glaucoma Eye Drop Program After Trial Failure $BLCO $DFAX https://stocktwits.com/news/equity/markets/blco-stock-drops-after-hours-after-company-halts-glaucoma-eye-drop-program/cZmYXNTR7Fb

0 · Reply

notreload_ai Jul. 9 at 9:05 PM

$BLCO announced that its Phase 2 study of BL1107 eye drops in glaucoma missed the primary endpoint. The company will discontinue the topical program but continue advancing a sustained-release implant for geographic atrophy. https://notreload.xyz/xy/blco-discontinues-bl1107-glaucoma-eye-drops/

0 · Reply

Market Cap	6.16B
Revenue (ttm)	5.10B
Net Income (ttm)	-360.00M
EPS (ttm)	N/A
PE Ratio	23.72
Forward PE	21.74
Profit Margin	-7.06%
Debt to Equity Ratio	0.79

Volume	460,100
Avg Vol	414,984
Day's Range	N/A - N/A
Shares Out	357.35M
Stochastic %K	17%
Beta	0.56
Analysts	Sell
Price Target	$19.29